Shiseido is currently facing a significant turning point, grappling with its toughest challenges in many years following some costly missteps in North America and increasing competition from nimble Asian brands. Once a strong competitor to industry giants like L’Oréal and Estée Lauder, this Japanese cosmetics powerhouse finds itself navigating turbulent waters.
Six years ago, Shiseido invested a staggering $845 million to acquire the American skincare brand Drunk Elephant, hoping to attract a younger customer base. Unfortunately, this investment has not panned out as expected, leading the company to write off more than half of that expenditure due to plummeting sales and profits.
This situation illustrates just how quickly beauty brands can lose their competitive edge amid shifting social trends, accelerated product development cycles, and the rise of Korean and Chinese brands that are reshaping the global cosmetics landscape. Companies like Amorepacific and Kolmar Korea have surpassed Shiseido, positioning themselves as the largest exporters to the U.S. market.
In an effort to regain its footing post-pandemic, Shiseido's management team, representing 154 years of expertise in cosmetics, has initiated a comprehensive turnaround strategy. This plan emphasizes substantial cost reductions and a renewed focus on its luxury offerings, particularly the high-end brand Clé de Peau Beauté.
However, investors have remained skeptical, as Shiseido's stock price has stagnated, lingering at just one-third of its value since reaching peak sales in 2019. Currently, the company's market capitalization stands at approximately ¥1.07 trillion, or about $6.8 billion.
Masakazu Takeda, a portfolio manager at Sparx Asia Investment Advisors Ltd., noted, "The Chinese and Korean competitors, along with U.S. firms, are not merely observing from the sidelines. In the past, it was straightforward—brands like Shiseido and Kao flew off the shelves. That simplicity has vanished."
A representative from Shiseido reaffirmed the company's commitment to its strategic growth initiatives, with a new business update set to be released in February alongside the report of its full-year earnings.
Last year, Shiseido cautioned investors that it anticipated recording its first operating loss in decades when it announces its full-year results in February, primarily attributed to a write-down related to Drunk Elephant.
Originally, this acquisition aimed to enhance Shiseido’s appeal among younger consumers seeking Instagram-worthy products featuring natural ingredients. Regrettably, the brand's performance quickly deteriorated in the fiercely competitive skincare market.
Challenges such as supply chain disruptions, marketing strategies perceived as overly directed at teenagers, and an influx of competitively priced brands touting similar "clean" ingredient claims have resulted in a staggering 49 percent revenue drop for the nine months ending in September.
Hisashi Arakawa, head of Japan equities at Aberdeen Investments, who held Shiseido stock for a decade before divesting in March 2024, remarked, "We are not in a position to consider repurchasing or reassessing our investment anytime soon."
These setbacks highlight Shiseido’s slow progress in tackling persistent issues, including revitalizing its product offerings and decreasing its dependency on the Chinese market. The company faces not only high fixed costs but also a lack of flexibility, challenges that reflect broader inefficiencies common among many large, historically rooted Japanese corporations.
To reposition itself effectively, Shiseido plans to implement cost-cutting measures totaling ¥25 billion this year by enhancing production efficiency, curtailing expenditures on external vendors, and streamlining corporate operations. In November, CEO Kentaro Fujiwara unveiled a growth strategy targeting an annual sales increase of 2 to 5 percent through 2030 while aiming for a core operating profit margin of at least 10 percent.
At the same time, Shiseido intends to strengthen its luxury brand portfolio, including Clé de Peau Beauté, while expanding mid-tier brands like Nars and enhancing its fragrance offerings with partnerships such as Max Mara. The company is also exploring opportunities in medical and dermal cosmetics.
As Shiseido makes strides in controlling costs, improving revenue growth through recovery in China and rejuvenating the Drunk Elephant brand will be crucial. Takashi Miyazaki, an analyst at Goldman Sachs Japan Co., emphasized, "For a company of Shiseido’s scale, it’s prudent to narrow down the brand focus and concentrate limited resources rather than pursuing further acquisitions."
Additionally, Shiseido must adjust to waning demand from China, which has slowed notably in the aftermath of the pandemic, coupled with general economic deceleration. Ongoing geopolitical tensions between Japan and China further complicate matters, as Chinese beauty brands continue to gain traction, negatively impacting the outlook for Japanese firms.
As activist investment firm Oasis Management Co. increases pressure on Kao to divest underperforming brands and sharpen global marketing strategies, Shiseido might also become a target if Fujiwara’s turnaround strategy fails to produce tangible results.
Independent Franchise Partners LLP, known for its advocacy efforts in 2020 for Kirin Holdings Co. to restructure, has now become Shiseido’s second-largest shareholder, holding approximately 8 percent of the company, according to Bloomberg data.
Ikuo Mitsui, a fund manager at Aizawa Securities Co., noted, "Considering that the management’s strategy remains somewhat flawed and hasn’t translated into actual success, there is potential for activists to challenge the current leadership. However, it remains uncertain whether this would lead to any positive changes in share price."
This evolving story raises intriguing questions: Can Shiseido successfully navigate this complex landscape and regain its former glory? Or is a fundamental transformation necessary for survival? Share your thoughts in the comments!
